How to ask the right questions at an authority meeting

Scientific advice meeting

Get things right in meetings with EMA, FDA, and the PMDA

One way or another, as a drug developer, you have to live with the answers and comments you get from authorities. Therefore, the essential message is: choose your questions carefully and avoid questions you don't need answers to.

The basics first - Why do you have to conduct regulatory meetings?

You may think that existing regulatory guidelines are clear and that your project plan is foolproof. However, there are still many good reasons to meet with the authorities. They know a lot that companies don't.

Firstly, they can learn from everything they see in other companies' plans and results. Secondly, existing guidelines are often a few years old. Hence, new knowledge may have raised the bar on what is required. Both in terms of the current situation and requirements might change over the years in the project.

Perhaps most important for a majority of companies - it is a way of reducing the risk of the project in the eyes of the outside world. For example, any seasoned investor will want to know how the authorities view your development plans. What will it take to start your subsequent clinical trial? What will ultimately be required to reach the market?

Content - What should the questions be about 

For a health agency (such as the MPA, EMA or FDA) to gather the right expertise for a scientific advice meeting, a drug developer must submit several specific questions to the agency.


In connection to these questions, you should have a "Company Position," i.e., your position on each question. The most important thing when formulating these is that there is a common thread in your arguments and facts to back them up. Here you may also realize that the choice of timing for meetings is crucial. When do you have enough knowledge and data to get your desired answers? Should some questions be saved for a later date? These are, unfortunately, only sometimes straightforward considerations.


Let's say the questions are vaguely phrased and the positions unclear or poorly justified. You then risk a situation where the authorities misunderstand essential aspects of the project. In the long run, this may lead to inadequate answers that are to your disadvantage.

Choose your questions carefully - Ask the right type of questions

So how should you ask questions to an authority? The perspective question first. Remember that the regulatory body isn't a consultancy that can help you craft your development plan. That's your job.

Instead, the questions should be about your plans (or problems/concerns, if you have any) and clarifications regarding, for example, quality (manufacturing, etc.), preclinical or clinical studies, methodology, and statistics. Regulatory topics may concern, for example, the choice of regulatory procedures or the possibility of obtaining various forms of expedited pathways.

How you get phrasing and wording on point 

It is not just that the questions need to be about the right things. Formulating them can be challenging, to say the least. My best tip is to keep the questions short and concise, rather than open and vague. Here's an example of a poorly worded question:

''What would a good clinical development plan look like for our product?''

The question is vague in both content and structure. It is open-ended and unspecific because it lacks a ''Company Position''. It is a question that you sort out yourself or with the help of consultants. It should also be evident that the company has done its homework, for example by referring to expert advice, relevant guidelines and prior knowledge in the field. Your own data as well as published data from others.

But we can fix this by including your position and keeping the question closed:

''Based on our Company Position, do you agree that the proposed clinical trial is sufficient to establish the dosing regimen for the pivotal study program?''

Scientific advice in different countries

Does it work differently in different countries? The short answer is: both yes and no. There are practical differences in the way national European authorities, EMA, FDA, PMDA (Japan) and other authorities hold their advisory meetings. Indeed, we have had to adapt to new procedures because of the pandemic. Physical meetings have been replaced by digital, or even just written responses. Other differences include costs, timelines and the extent of background documentation that should be provided.

Despite the differences, however, the challenges for those developing a medicine are more or less the same. Asking the right questions at the right time and having a well-founded, red thread in your argumentation are still the keys to successful regulatory meetings.

Need help with preparing for a scientific advice meeting? 

You might find yourself in need of getting in touch with regulators for scientific meetings at any stage of the drug development program. SDS can help you to identify key questions to ask authorities, prepare the meeting package and justifications, join you for the meeting and write minutes. In other words, support you throughout the entire regulatory process. 

Getting in touch with us below is a good start. 👇


Contact our director of Regulatory Affairs

Send your inquiry to Erika Spens

We use cookies to ensure that we give you the best experience on our website. Read our cookie policy here.